RLAY (Relay Pharma) Likuiditas cepet

Relay Therapeutics (RLAY) price action reflects the current 17.60 metric. The business relies on digital modeling, which reduces reagent consumption and aligns with ESG standards. The team integrates chemists and IT specialists attracted by complex computations and options. High barriers to entry are ensured by billions in investments, molecule patents, and strict FDA regulatory requirements for innovative drugs.

Relay Corp (RLAY) - Likuiditas kritis saka 04.07.2022 nganti 29.10.2026

relaytx.com (RLAY) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:

Bagan rega Relay Pharma|RLAY - Bagan rega target

- indikator valuasi pasar bisnis:

Nilai pasar Relay Pharma|RLAY - Total Nilai Perusahaan

- data kapitalisasi buku:

Nilai Buku saben Saham Relay Therapeutics|RLAY - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih relaytx.com|RLAY - Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

Rasio Total Utang marang Ekuitas Relay Therapeutics|RLAY - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Relay Therapeutics, Inc.|RLAY - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Relay Pharma|RLAY - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Relay Therapeutics|Rasio cepet relaytx.com

- indikator bathi lan kelipatan valuasi:

RLAY - Bathi resik taunan

Pambiji fundamental perusahaan:Relay Pharma - RLAY

To stress-test assets, it is critical for an investor to evaluate a company's ability to meet short-term obligations excluding low-liquidity inventories. Since Relay Therapeutics (RLAY) focuses on the costly development of targeted cancer drugs, the current quick ratio reflects the actual reserve of cash and accounts receivable, determining the business's financial stability during the period leading up to the commercialization of innovative medicines.

Analisis pesaing